



## Safety and Immunogenicity of the COVID-19 Vaccine

Guest Editor:

**Dr. Johad F. Khoury**

Yale School of Medicine, New  
Haven, CT 06520-8023, USA

Deadline for manuscript  
submissions:

**closed (31 March 2024)**

### Message from the Guest Editor

Dear Colleagues,

COVID-19 vaccines were instant gamechangers when they were introduced in late 2020. Their effect on mortality and severe morbidity and, as a result, on public activities has been tremendous.

On the other hand, some concerns and questions were raised regarding the safety and immunogenicity of these vaccines, both in the general population and in certain risk groups. While data continue to emerge from trials around the world, global policy-making agencies are publishing and updating guidelines and recommendations.

In this Special Issue, we aim to publish the most up-to-date trials regarding the safety of or concerns around COVID-19 vaccines, regardless of the vaccine type or manufacturer, and the immunogenicity that these vaccines provide over time, in the general population as well as in special risk groups.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)